Search results
PFC, REC get 'buy' rating from Bernstein; up to 23% upside seen in power financier stocks
CNBC Awaaz· 6 days agoREC has delivered multibagger returns of 224 percent in one year, more than quadrupling investors'...
[Exclusive] itel Color Pro 5G with colour-changing back to launch in India this month
91 Mobiles· 20 hours agoTeam 91mobiles exclusively brings you the details of the itel Color Pro 5G, courtesy of industry...
Sell Indus Tower; target of Rs 270: ICICI Securities
CNBC Awaaz· 5 days agoICICI Securities is bearish on Indus Tower has recommended sell rating on the stock with a target price of Rs 270 in its research report dated July 04,...
Stocks To Watch: HDFC Bank, Bajaj Auto, Raymond, PNB, Ircon, RBL Bank And Others - News18
News18· 4 days agoStocks to watch: Shares of firms like HDFC Bank, Bajaj Auto, Raymond, PNB, Ircon, RBL Bank, and others will be in focus on Friday's trade.
Bansal Wire IPO: Issue subscribed 2.5x times on Day 2; NIIs frontrunners
CNBC Awaaz· 5 days agoThe IPO consists solely of a fresh issue, ensuring all proceeds (excluding IPO expenses) will...
Emcure Pharma IPO: Issue subscribed 29% on Day 1 so far; NIIs lead from the front
CNBC Awaaz· 6 days agoA day before the drugmaker's public offer went live, Emcure Pharmaceuticals raised Rs 582.6 crore...
Taking Stock: Market hits new milestone; bank, metal, power outshine
CNBC Awaaz· 6 days agoAmong sectors, except media, all other sectoral indices ended in the green with power, capital...
Allied Blenders and Distillers: Should you buy, sell or hold after listing?
CNBC Awaaz· 7 days agoWhile promising macro situation are likely to help the company experience growth, the issue seems to...
Subscribe Emcure Pharmaceuticals Ltd; KR Choksey
CNBC Awaaz· 6 days agoKR Choksey, has come out with its report on Emcure Pharmaceuticalss Ltd. The research firm has recommended to “ Subscribe- Long Term” the ipo in its research report as on July 02 2024.
Subscribe- Long Term Emcure Pharmaceuticals Ltd; Anand Rathi
CNBC Awaaz· 7 days agoAnand Rathi, has come out with its report on Emcure Pharmaceuticals Ltd. The research firm has recommended to “ Subscribe- Long Term” the ipo in its research report as on July 02 2024.